MRKR Marker Therapeutics Inc.

5.92
+0.01  (+0%)
Previous Close 5.91
Open 5.87
Price To Book 296
Market Cap 268594514
Shares 45,370,695
Volume 222,560
Short Ratio
Av. Daily Volume 276,518

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due by the end of 2019.
TPIV200
Platinum-sensitive ovarian cancer
26/27 patients have shown immune response.
TPIV200
Second line triple-negative breast cancer (TNBC)
Phase 1 data presented at ASH 2018.
MultiTAA-Specific T Cells
Acute Lymphoblastic Leukemia
Phase 1/2 data presented at ASH 2018.
MultiTAA-Specific T Cells
Multiple Myeloma
Phase 1/2 trial ongoing.
MultiTAA-Specific T Cells
Lymphoma

Latest News

  1. Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
  2. Marker Therapeutics to Present at the CAR-TCR Summit Europe
  3. Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility
  4. Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
  5. Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference
  6. Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?
  7. Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019
  8. The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
  9. Marker Therapeutics Provides Updates of its Lead Clinical Programs
  10. These 4 Healthcare Stocks May Test December Highs
  11. Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit
  12. The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
  13. Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
  14. Marker Therapeutics to Present at Three Upcoming Healthcare Conferences
  15. Marker Therapeutics, Inc. Announces New Executive Appointments
  16. Marker to Present at Two Upcoming Cellular Therapy Conferences